Tibet Rhodiola Pharmaceutical Holding Co (600211) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.072x

Based on the latest financial reports, Tibet Rhodiola Pharmaceutical Holding Co (600211) has a cash flow conversion efficiency ratio of 0.072x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥297.86 Million ≈ $43.59 Million USD) by net assets (CN¥4.17 Billion ≈ $609.56 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Tibet Rhodiola Pharmaceutical Holding Co (600211) balance sheet quality index to measure how much of total assets are equity-financed.

Tibet Rhodiola Pharmaceutical Holding Co - Cash Flow Conversion Efficiency Trend (1999–2025)

This chart illustrates how Tibet Rhodiola Pharmaceutical Holding Co's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 600211 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Tibet Rhodiola Pharmaceutical Holding Co Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tibet Rhodiola Pharmaceutical Holding Co ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Bros Eastern Co Ltd SHG:601339	0.071x
Xiamen ITG Group Corp Ltd SHG:600755	0.080x
Sirius Real Estate Ltd JSE:SRE	0.019x
Arena Star Group Ltd TA:ARNA	-0.016x
Watsco Inc NYSE:WSO-B	-0.006x
Fidelis Insurance Holdings Limited NYSE:FIHL	0.102x
Capri Holdings Ltd NYSE:CPRI	1.874x
Beijing New Oriental Star Petrochemical Engineering Co Ltd SHE:002755	0.057x

Annual Cash Flow Conversion Efficiency for Tibet Rhodiola Pharmaceutical Holding Co (1999–2025)

The table below shows the annual cash flow conversion efficiency of Tibet Rhodiola Pharmaceutical Holding Co from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see 600211 stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥4.17 Billion ≈ $609.56 Million	CN¥1.03 Billion ≈ $150.24 Million	0.246x	-2.08%
2024-12-31	CN¥3.95 Billion ≈ $578.32 Million	CN¥994.79 Million ≈ $145.57 Million	0.252x	-21.53%
2023-12-31	CN¥3.37 Billion ≈ $493.67 Million	CN¥1.08 Billion ≈ $158.35 Million	0.321x	+16.10%
2022-12-31	CN¥3.03 Billion ≈ $443.50 Million	CN¥837.38 Million ≈ $122.53 Million	0.276x	+99.38%
2021-12-31	CN¥2.65 Billion ≈ $387.05 Million	CN¥366.53 Million ≈ $53.64 Million	0.139x	-16.23%
2020-12-31	CN¥2.59 Billion ≈ $378.76 Million	CN¥428.17 Million ≈ $62.65 Million	0.165x	-17.33%
2019-12-31	CN¥2.45 Billion ≈ $358.04 Million	CN¥489.59 Million ≈ $71.64 Million	0.200x	+56.16%
2018-12-31	CN¥2.26 Billion ≈ $330.29 Million	CN¥289.22 Million ≈ $42.32 Million	0.128x	+186.57%
2017-12-31	CN¥2.05 Billion ≈ $299.31 Million	CN¥91.46 Million ≈ $13.38 Million	0.045x	-88.24%
2016-12-31	CN¥658.19 Million ≈ $96.31 Million	CN¥250.21 Million ≈ $36.61 Million	0.380x	+37.92%
2015-12-31	CN¥485.90 Million ≈ $71.10 Million	CN¥133.93 Million ≈ $19.60 Million	0.276x	+180.74%
2014-12-31	CN¥414.18 Million ≈ $60.61 Million	CN¥-141.40 Million ≈ $-20.69 Million	-0.341x	-148.81%
2013-12-31	CN¥399.20 Million ≈ $58.42 Million	CN¥279.22 Million ≈ $40.86 Million	0.699x	+379.69%
2012-12-31	CN¥385.44 Million ≈ $56.40 Million	CN¥56.20 Million ≈ $8.22 Million	0.146x	+328.05%
2011-12-31	CN¥354.94 Million ≈ $51.94 Million	CN¥12.09 Million ≈ $1.77 Million	0.034x	+481.16%
2010-12-31	CN¥324.19 Million ≈ $47.44 Million	CN¥1.90 Million ≈ $278.05K	0.006x	-90.17%
2009-12-31	CN¥300.00 Million ≈ $43.90 Million	CN¥17.88 Million ≈ $2.62 Million	0.060x	-22.44%
2008-12-31	CN¥279.15 Million ≈ $40.85 Million	CN¥21.46 Million ≈ $3.14 Million	0.077x	+215.24%
2007-12-31	CN¥274.28 Million ≈ $40.14 Million	CN¥-18.30 Million ≈ $-2.68 Million	-0.067x	-178.61%
2006-12-31	CN¥396.34 Million ≈ $58.00 Million	CN¥33.63 Million ≈ $4.92 Million	0.085x	+76.37%
2005-12-31	CN¥393.25 Million ≈ $57.54 Million	CN¥18.92 Million ≈ $2.77 Million	0.048x	-22.12%
2004-12-31	CN¥435.51 Million ≈ $63.73 Million	CN¥26.90 Million ≈ $3.94 Million	0.062x	-44.44%
2003-12-31	CN¥424.53 Million ≈ $62.12 Million	CN¥47.20 Million ≈ $6.91 Million	0.111x	+41.76%
2002-12-31	CN¥418.85 Million ≈ $61.29 Million	CN¥32.85 Million ≈ $4.81 Million	0.078x	+106.06%
2001-12-31	CN¥406.50 Million ≈ $59.48 Million	CN¥15.47 Million ≈ $2.26 Million	0.038x	-25.49%
2000-12-31	CN¥402.35 Million ≈ $58.88 Million	CN¥20.55 Million ≈ $3.01 Million	0.051x	+786.04%
1999-12-31	CN¥389.71 Million ≈ $57.03 Million	CN¥2.25 Million ≈ $328.81K	0.006x	--

About Tibet Rhodiola Pharmaceutical Holding Co

SHG:600211 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.79 Billion

CN¥12.22 Billion CNY

Market Cap Rank

#6537 Global

#1323 in China

Share Price

CN¥37.91

Change (1 day)

-1.79%

52-Week Range

CN¥35.31 - CN¥56.43

All Time High

CN¥165.99